Location: France
Total raised: $165M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.06.2026 | Series A | $165M | Sofinnova ... |
Mentions in press and media 5
| Date | Title | Description |
| 22.06.2026 | Bionyra Pharma Raises $165 Million Series A To Advance Biologics For Inflammatory Diseases | Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Heal... |
| 22.06.2026 | Bionyra Pharma Raises $165M to Advance Next-Generation Immune Disease Treatments | Bionyra Pharma Launches With $165M Series A Financing Bionyra Pharma, a clinical-stage biotech, is taking flight out of stealth after raising $165 million Series A funding to advance a portfolio of biologic drugs designed to treat immune-me... |
| 22.06.2026 | Bionyra Pharma Raises $165M in Series A Funding | Bionyra Pharma, a Paris, France- and Boston, MA-based clinical-stage biopharmaceutical company developing new biologics for immune-mediated inflammatory diseases, raised $165M in Series A funding. The round was led by Jeito Capital and Sofi... |
| 22.06.2026 | Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets | For Bionyra Pharma co-founder and CEO Frédéric Marrache, M.D., Ph.D., “the planets had to align” to pull him out of his R&D VP role at Sanofi. But after weighing the opportunity to lead immunology and inflammation (I&I) biotech, he ... |
| - | Bionyra | - |